Euronext Paris-listed Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has sold its minority stake in a Chinese biopharmaceutical company to receive US$15.3m. Following this transaction, Transgene reaffirms its financial visibility until early 2024. …
Home Healthcare Markets International News France: Transgene reaffirms financial visibility with sale of stake in Chinese company